Anixa Biosciences Stock News

The United States Treasury Secretary, Janet Yellen, recently expressed her confidence in the economy's ability to recover from the recession without causing significant harm to the job market or spark

ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.

Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

ANIXA BIOSCIENCES INC (ANIX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

SAN JOSE, Calif. , Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announ

Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector

Here is how ANIXA BIOSCIENCES INC (ANIX) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

Anixa Biosciences (ANIX) has added ~6.5% in the pre-market after announcing that in early lab studies, a molecule developed by the company and partner MolGenie GmbH was more potent…

Anixa Biosciences Inc (ANIX) shares closed today at 1.5% above its 52 week low of $2.74, giving the company a market cap of $83M. The stock is currently down 6.4% year-to-date, down 18.7% over the past 12 months, and down 48.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 17.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -563.0% The company's stock price performance over the past 12 months lags the peer average by 210.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Anixa Biosciences Inc. (NASDAQ:ANIX) price closed higher on Tuesday, December 07, jumping 3.35% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.

Anixa Biosciences Inc (NASDAQ: ANIX ) announced the results of a genomic variant analysis conducted with its partner, MolGenie GmbH , on potential compounds to treat COVID-19. The data indicate that the compounds in development should be effective against the Omicron variant, in addition to the previously identified Delta variant Full story available on Benzinga.com

In the latest trading session, 0.84 million Anixa Biosciences Inc. (NASDAQ:ANIX) shares changed hands as the companys beta touched 1.75. With the companys most recent per share price at $3.37 changing hands around $0.24 or 7.67% at last look, the market valuation stands at $97.66M. ANIXs current price is a discount, trading about -140.06% off Anixa Biosciences Inc. (NASDAQ: ANIX): The Stock For Success Over The Next Few Months Read More »